NCT06676085

A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation

A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Beijing Chao Yang Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

ECMO is widely used in patients with refractory respiratory and/or circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.

Conditions

• ECMO

Interventions

Type	Name	Description
DRUG	Nafamostat	Nafamostat combined with unfractionated heparin for anticoagulation
DRUG	Heparin	unfractionated heparin for anticoagulation

Timeline

• Start date: 2024-11-01
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2024-11-06
• Last updated: 2024-11-18

Locations

1 site across 1 country: China